Jim Cramer Says Haleon’s “Stock’s Been Struggling”

Haleon plc (NYSE:HLN) is one of the stocks Jim Cramer recently discussed. Cramer highlighted the stock’s struggles, as he commented:

“With Kimberly-Clark shelling out nearly $49 billion to buy Kenvue, which was originally J&J’s over-the-counter medicine business, I think it’s time to check in with Haleon, the former consumer business of GlaxoSmithKline and Pfizer… Oh, they’ve got a ton of big brands, and you know them all: Advil, Sensodyne, Theraflu, among many others. But the stock’s been struggling, pulling back from the north of $11 in June to $9 and change as of today. Hey, late last week, Haleon reported, and the results were generally in line with expectations, a slightly better-than-expected 3.4% organic revenue growth. The company seems to be in a tough space in North America… but they’ve got terrific growth, Latin America, I like India, really some great overseas.”

A stock market graph. Photo by energepic.com

Haleon plc (NYSE:HLN) develops consumer healthcare products across oral care, pain relief, respiratory, digestive health, and supplements.

While we acknowledge the potential of HLN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.

View Comments